psi-6206-13cd3

Description: PSI-6206 13CD3 (RO-2433 13CD3; GS-331007 13CD3; Sofosbuvir metabolite GS-331007 13CD3) is the deuterium labeled form of PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 inhibits HCV replicon with EC90 of > 100 uM. Sofosbuvir (also known as PSI-7977, GS-7977; trade names Sovaldi and Virunon) is a HCV NS5B polymerase inhibitor that is used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir acts by inhibiting the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It is a component of the first all-oral, interferon-free regimen approved for treating chronic Hepatitis C. In 2013, the FDA approved sofosbuvir in combination with ribavirin (RBV) for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive patients with HCV genotypes 1 and 4.

References: J Biol Chem. 2010 Nov 5; 285(45):34337-47; J Med Chem. 2010 Oct 14; 53(19):7202-18; Antimicrob Agents Chemother. 2012 Jun; 56(6):3359-68.

Related CAS#:1621884-22-7 (PSI-7409 tetrasodium); 1015073-42-3 (PSI-7409); 1190307-88-0 (Sofosbuvir); 1496552-51-2 (Sofosbuvir impurity K); Sofosbuvir impurity I; 1394157-34-6 (Sofosbuvir impurity N); Sofosbuvir impurity L; Sofosbuvir impurity H; 1334513-10-8 (Sofosbuvir impurity J); 1496552-16-9 (Sofosbuvir impurity A); 2095551-10-1 (Sofosbuvir impurity M); 1337482-17-3 (Sofosbuvir impurity F); 1337482-15-1 (Sofosbuvir impurity G); 1496552-28-3 (Sofosbuvir impurity C); Sofosbuvir impurity E; Sofosbuvir impurity B; Sofosbuvir impurity D; Sofosbuvir 13CD3; Sofosbuvir D6; Enantiomer of Sofosbuvir; 1157884-58-6 (Sofosbuvir Impurity 32)